Baidu
map

痣少的患者可能意味着其黑色素瘤的侵袭性更高

2015-08-23 MedSci MedSci原创

痣少的患者可能意味着其黑色素瘤的侵袭性更高身上痣的数目多余50的个体患黑色素瘤的风险会增加,但是少于50个痣的个体也应警惕黑色素瘤的发生。据2015年美国皮肤学院夏季会议的一项最新研究显示,与痣多的人相比,痣少的人发生侵袭性更强的黑色素瘤的风险更大。Dr. Kim说道,对于身上痣多余50个的人来说,他们可能更清楚自己患癌的风险,更可能去皮肤科筛查,然而,在治疗晚期皮肤黑色素瘤病例时,她发现,身上痣

身上痣的数目多余50的个体患黑色素瘤的风险会增加,但是少于50个痣的个体也应警惕黑色素瘤的发生。据2015年美国皮肤学院夏季会议的一项最新研究显示,与痣多的人相比,痣少的人发生侵袭性更强的黑色素瘤的风险更大。

Dr. Kim说道,对于身上痣多余50个的人来说,他们可能更清楚自己患癌的风险,更可能去皮肤科筛查,然而,在治疗晚期皮肤黑色素瘤病例时,她发现,身上痣更少的患者其黑色素瘤的侵袭性更强。


为了探究痣多与痣少之间黑色素瘤的差别,Dr. Kim及其同事回顾分析了281例黑色素瘤患者。89名患者身上痣的数目多余50个,其余192名患者身上痣的数目低于50个。

结果发现,相对于痣多的患者,痣少的患者其黑色素瘤更厚、侵袭性更强;痣多且不典型的患者其黑色素瘤更薄且侵袭性更弱。此外,与痣多的患者相比,痣少的患者诊断出黑色素瘤的年龄更小。
Dr. Kim认为她们的研究结果可能是由几个因素所造成。卫生保健提供者可以很容易的确定痣多于50个的个体患癌的风险更大,并告知患者重视其患癌风险。其结果是,这些人更可能定期去接受皮肤检查,因而便可在黑色素瘤早期,较薄且侵袭性较弱的时候检测出来。

此外,痣多与痣少患者存在生物学上的差异,而且这些差异可能是导致黑色素瘤存在差异的原因。Dr. Kim说道,“我们已经知道,导致黑色素瘤发生的突变的基因并不完全相同。这两种患者发生黑色素瘤的途径很可能并不相同,导致了黑色素瘤侵袭性的不同。如果痣少的患者更易发生侵袭性更强的黑色素瘤,那么我们就需要确保他们也接受教育和筛查。”

Dr. Kim表示仍需要更大规模的研究以证实她们的研究成果。进一步探究这两组患者黑色素瘤的生物学特性将十分重要,研究人群皮肤癌筛查的益处意味着扩大皮肤癌检查工作的必要性。
“这项研究提醒我们,每个人都需要警惕黑色素瘤,不管他们身上痣多还是少,”Dr. Kim说道,“确保你知道如何识别皮肤癌发生时的迹象,且在怀疑患癌时及时就诊。”

原始出处:

Study: Fewer Moles May Mean More Aggressive Melanoma.Newswise,17-Aug-2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680303, encodeId=67661680303e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Oct 06 06:41:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366241, encodeId=a4a013662412f, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487611, encodeId=98bc148e611a7, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558718, encodeId=e47c1558e18a5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564727, encodeId=38541564e27c6, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=)]
    2015-10-06 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680303, encodeId=67661680303e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Oct 06 06:41:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366241, encodeId=a4a013662412f, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487611, encodeId=98bc148e611a7, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558718, encodeId=e47c1558e18a5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564727, encodeId=38541564e27c6, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=)]
    2015-08-24 sunyl07
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680303, encodeId=67661680303e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Oct 06 06:41:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366241, encodeId=a4a013662412f, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487611, encodeId=98bc148e611a7, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558718, encodeId=e47c1558e18a5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564727, encodeId=38541564e27c6, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=)]
    2015-08-24 yese
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680303, encodeId=67661680303e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Oct 06 06:41:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366241, encodeId=a4a013662412f, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487611, encodeId=98bc148e611a7, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558718, encodeId=e47c1558e18a5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564727, encodeId=38541564e27c6, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680303, encodeId=67661680303e1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Tue Oct 06 06:41:00 CST 2015, time=2015-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366241, encodeId=a4a013662412f, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487611, encodeId=98bc148e611a7, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558718, encodeId=e47c1558e18a5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564727, encodeId=38541564e27c6, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Mon Aug 24 15:41:00 CST 2015, time=2015-08-24, status=1, ipAttribution=)]

相关资讯

JAMA Oncol:nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效

    抗PD-1的治疗性抗体,nivolumab,已经证明在治疗晚期黑素瘤方面有临床活性。nivolumab对于具有野生型BRAF激酶的肿瘤患者亚群 VS 有BRAF突变的肿瘤患者的活性在一个大的数据集还没有系统地进行探索。该研究的目的是评估nivolumab治疗野生型BRAF的患者和突变体BRAF转移性黑素瘤患者的疗效性和的安全性。    这项回顾性分析

NEJM:Nivolumab和易普利姆玛联合或单药治疗未经治疗过的黑色素瘤

    背景  Nivolumab(一个程序性死亡1[PD-1]检查点抑制剂)和易普利姆玛(一种细胞毒性T淋巴细胞相关抗原4[CTLA-4]检查点抑制剂)已被证明在转移性黑色素瘤中具有互补活性。这项随机,双盲,3期研究对nivolumab单独或nivolumab加易普利姆玛与易普利姆玛单独治疗转移性黑色素瘤患者进行了比较。    方法  

Nat Genet:科学家确定了黑色素瘤第三常见突变基因

众所周知,基因突变在黑色素瘤的发生中扮演着重要的作用,而且已经确定了许多突变的基因和基因组。然而,约30%的黑色素瘤其突变基因仍未清楚。目前,一项新的研究已经确定了存在于大量黑色素瘤中的一组基因突变,并确定了一个主要的突变基因。该研究结果发表于《自然遗传学》杂志上,研究人员来自耶鲁大学,他们希望可通过此发现开发更多针对黑色素瘤的靶向治疗方法。研究人员证实,NF1是黑色素瘤发生过程中主要基因。文中,

肿瘤免疫疗法——多突变癌症克星

肿瘤中的基因突变越多,新免疫疗法就越有效。人类结肠癌细胞。图片来源:URBAIN WEYEMI, CHRISTOPHE E. REDON, WILLIAM M. BONNER 临床试验中使用的新型免疫系统激活抗癌药物让许多看似无法治愈的黑素瘤或肺癌患者重获新生,但这些药物对结肠癌似乎无效。不过有一个例外——一位男性患者的结肠癌转移瘤在2007年接受药物治疗后消失了——引起了研究人员的兴趣

Sci Rep:不用活检也可以快速检测皮肤恶性黑色素瘤

研究人员已经研发出一种新的非侵入性技术,它可以准确地发现机体没有进行过活检的恶性黑色素瘤。这项发表在自然科学报告的研究表明,通过利用一种特殊的技术——使用激光检测血液流动的细微差别,使研究人员可以区别恶性黑色素瘤和非恶性痣,并及早开始肿瘤治疗方案。在研究过程中,兰开斯特大学和意大利比萨大学的研究人员经由比萨大学医院55例不典型痣患者的同意,使用激光多普勒系统对他们的皮肤进行检测和研究。30分钟内用

Molecular cell:关键突变导致癌细胞代谢“重连”促进药物抵抗

                                                       &nbs

Baidu
map
Baidu
map
Baidu
map